Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.45 |
| ▸ | SCN1A | P35498 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | SCN2B | O60939 | 1/20 | 0.43 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16175324 | 0.88 | SCN9A (0.54) | SCN9ASCN5ASCN1AABCB11CYP2C9 | |
| SCHEMBL16175265 | 0.87 | SCN9A (0.58) | SCN9ASCN5ASCN1ASCN2BSCN1B | |
| SCHEMBL16175377 | 0.86 | SCN9A (0.53) | SCN9ASCN5A | |
| SCHEMBL16175204 | 0.86 | SCN9A (0.53) | SCN9ASCN5ASCN1AABCB11CYP2C9 | |
| SCHEMBL365530 | 0.81 | SCN9A (0.56) | SCN9ASCN5ASCN1AABCB11CYP2C9 | |
| SCHEMBL366574 | 0.81 | SCN9A (0.56) | SCN9ASCN5A | |
| SCHEMBL16175451 | 0.81 | SCN9A (0.51) | SCN9ASCN5ASCN1ASCN2BSCN1B | |
| SCHEMBL363151 | 0.80 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL16175108 | 0.80 | SCN9A (0.51) | SCN9ASCN5ASCN1AABCB11CYP2C9 | |
| SCHEMBL365882 | 0.80 | SCN9A (0.53) | SCN9ASCN5ASCN1AABCB11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 25/4885SCN5A 4/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.